Keryx Biopharmaceuticals Announces Fourth Quarter and Year-End 2012 Financial Results
NEW YORK, March 11, 2013 -- /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced its results for the fourth quarter and year ended December 31, 2012.